Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Given Consensus Rating of “Reduce” by Analysts

Posted by George Bondi on Sep 5th, 2026

Carl Zeiss Meditec AG (OTCMKTS:CZMWY – Get Free Report) has earned an average rating of “Reduce” from the six analysts that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating on the company.

A number of research firms have weighed in on CZMWY. UBS Group cut Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research report on Tuesday, August 11th. Morgan Stanley assumed coverage on Carl Zeiss Meditec in a report on Wednesday. They set an “underweight” rating for the company. Finally, Zacks Research lowered shares of Carl Zeiss Meditec from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th.

Check Out Our Latest Stock Report on Carl Zeiss Meditec

Carl Zeiss Meditec Stock Performance

Shares of CZMWY stock opened at $36.61 on Friday. Carl Zeiss Meditec has a 52-week low of $26.65 and a 52-week high of $55.94. The stock’s 50-day moving average price is $34.59 and its 200 day moving average price is $31.59.

About Carl Zeiss Meditec

(Get Free Report)

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.